The earnings call highlighted Kenvue's efforts in improving gross margins, investing in brand growth, and achieving share gains in the self-care segment. However, these positive developments were tempered by underperformance in organic sales growth, distribution challenges in China, and a decline in the pediatric pain franchise due to a weak flu season. The outlook for 2025 is cautiously optimistic, with expected improvements in operational efficiency and strategic investments, but also acknowledges external economic challenges.

Company Guidance

During the Kenvue Fourth Quarter and Full-Year 2024 Earnings Conference Call, the company provided guidance for 2025, projecting organic sales growth of 2% to 4% and adjusted diluted EPS to be flat to up 2%, considering a mid-single-digit headwind from currency. For 2024, Kenvue reported organic sales growth of 1.5%, with adjusted diluted EPS of $1.14, which was within their guidance range. The company also achieved a 200 basis points increase in adjusted gross margin to 60.4%. Kenvue plans to launch 40% more innovations in 2025 and expects revenue growth to accelerate in the second half of the year, driven by stronger brand investments, improved distribution, and competitive trade and marketing initiatives. The company aims to realize $350 million in annualized savings by 2026 through operational efficiencies and cost structure optimization, which will support continued investments in brand growth.

Improved Adjusted Gross Margin

Kenvue expanded its adjusted gross margin by 200 basis points year-over-year to 60.4%, driven by strong productivity enhancements.

Significant Brand Investments

The company increased its total brand investment for the year by about 20%, raising its advertising budget to 10.6% of sales in 2024 compared to 8.7% in the prior year.

Self-Care Segment Share Gains

The self-care segment saw nearly 80% of its brands gaining market share, including major brands like Tylenol, Zyrtec, and Nicorette.

Progress in Skin Health and Beauty

Kenvue achieved volume-led growth in the skin health and beauty segment, particularly with strong performances in EMEA and Latin America.

Increased Productivity and Savings

Kenvue is on track to deliver $350 million of annualized savings by 2026 through its 'view forward' initiative, with significant costs taken out of its infrastructure.

---

Kenvue, Inc. (KVUE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KVUE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 13, 2025	2025 (Q1)	0.23 / -	0.28	―	―	―
Feb 06, 2025	2024 (Q4)	0.26 / 0.26	0.31	-16.13% (-0.05)
Nov 07, 2024	2024 (Q3)	0.27 / 0.28	0.31	-9.68% (-0.03)
Aug 06, 2024	2024 (Q2)	0.28 / 0.32	0.32	0.00% (0.00)
May 07, 2024	2024 (Q1)	0.25 / 0.28	0.33	-15.15% (-0.05)
Feb 08, 2024	2023 (Q4)	0.28 / 0.31	0.28	10.71% (+0.03)
Oct 26, 2023	2023 (Q3)	0.31 / 0.31	0.31	0.00% (0.00)
Jul 20, 2023	2023 (Q2)	0.30 / 0.32	0.315	1.59% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

KVUE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 06, 2025	$20.54	$19.60	-4.58%
Nov 07, 2024	$22.09	$22.55	+2.08%
Aug 06, 2024	$17.68	$20.28	+14.71%
May 07, 2024	$18.35	$19.52	+6.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---